West Pharmaceutical Services reported net sales of $874.5 million for the third quarter of 2026, a 8.7% increase over the prior year. The company recognized a $55.7 million pre-tax gain from the sale of its SmartDose® 3.5mL On-Body Delivery System to AbbVie, contributing to a significant increase in net income to $214.0 million for the quarter.
West Pharmaceutical Services reported third-quarter 2026 net sales of $874.5 million, an 8.7% increase driven by strong organic growth in its High-Value Product (HVP) Components business. Due to the strong performance, the company raised its full-year 2026 net sales guidance to a range of $3.41 billion to $3.42 billion and its adjusted-diluted EPS guidance to $9.38 to $9.48.
Term
Q3 2026
“I am pleased to report strong third-quarter 2026 results, with net sales and adjusted EPS exceeding our expectations. Our results were again led by our High-Value Product (HVP) Components business. The robust sales performance drove strong operating income margin expansion and EPS growth. As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance.”
Michel Lagarde, President and Chief Executive Officer
“I want to thank our global teams for their relentless focus on execution to deliver products and services for our customers and the patients they serve. West is a critical primary containment and drug delivery partner for pharmaceutical companies, biotechs and CDMOs around the world. We are grateful for the trust our customers put in us, and we remain committed to driving continuous improvement to even better serve their current and future needs.”
Michel Lagarde, President and Chief Executive Officer